Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The sphingosine-1-phospate receptor modulator fingolimod aggravates murine epidermolysis bullosa acquisita.

Thieme M, Bieber K, Sezin T, Wannick M, Gupta Y, Kalies K, Ludwig RJ, Mousavi S, Zillikens D, Sadik CD.

J Invest Dermatol. 2019 Jun 6. pii: S0022-202X(19)31630-6. doi: 10.1016/j.jid.2019.03.1159. [Epub ahead of print] No abstract available.

PMID:
31176709
2.

Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases.

Wannick M, Bezdek S, Guillen N, Thieme M, Meshrkey F, Mousavi S, Seeling M, Nimmerjahn F, M├│csai A, Zillikens D, Sezin T, Sadik CD.

Pharmacol Res Perspect. 2018 Nov 8;6(6):e00438. doi: 10.1002/prp2.438. eCollection 2018 Dec.

3.

Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.

Schlegel V, Thieme M, Holzmann C, Witt M, Grittner U, Rolfs A, Wree A.

Int J Mol Sci. 2016 Nov 9;17(11). pii: E1866.

4.

Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.

Thieme M, Zillikens D, Sadik CD.

Exp Dermatol. 2017 Mar;26(3):206-210. doi: 10.1111/exd.13174. Epub 2017 Feb 2. Review.

PMID:
27574180
5.

SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.

Werner M, Piorkowski M, Thieme M, Nanning T, Beschorner U, Rastan A, Zeller T, Scheinert D.

J Endovasc Ther. 2013 Dec;20(6):759-66. doi: 10.1583/13-4430R.1.

PMID:
24325691

Supplemental Content

Loading ...
Support Center